Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Usana Health SciencesUSNA -0.27%68 Debt-to-EBITDA is 0.14 as of Mar. 2026, which is 180% above its 10-year median of 0.05. GuruFocus rates USNA with a GF Score™ of 68/100 and a GF Value™ of $41.46 (Possible Value Trap). The stock has 7 warning signs investors should review. Among 1,550 Consumer Packaged Goods companies, Usana Health Sciences ranks better than 88.32% on this metric.
Debt-to-EBITDA measures a company's ability to pay off its debt.
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
The historical rank and industry rank for Usana Health Sciences's Debt-to-EBITDA or its related term are showing as below:
USNA'
s Debt-to-EBITDA Range Over the Past 10 Years
Min: 0.04 Med: 0.05 Max: 0.29
Current: 0.18
During the past 13 years, the highest Debt-to-EBITDA Ratio of Usana Health Sciences was 0.29. The lowest was 0.04. And the median was 0.05.
USNA's Debt-to-EBITDA is ranked better than 88.32% of 1550
companies
in the Consumer Packaged Goods industry
Industry Median: 2.075
vs USNA: 0.18
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.
According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
Usana Health Sciences Debt-to-EBITDA Related Terms
Usana Health Sciences Debt-to-EBITDA Historical Data
* Premium members only.
The historical data trend for Usana Health Sciences's Debt-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
USNA vs ENHA, NATR, AMNF: Debt-to-EBITDA Comparison
For the Packaged Foods subindustry, Usana Health Sciences's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Usana Health Sciences Debt-to-EBITDA vs Consumer Packaged Goods Industry
For the Consumer Packaged Goods industry and Consumer Defensive sector, Usana Health Sciences's Debt-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Usana Health Sciences's Debt-to-EBITDA falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data,
the EBITDA data used here is four times the quarterly (Mar. 2026) EBITDA data.
Usana Health Sciences (USNA) has a Debt-to-EBITDA of 0.14 as of Mar. 2026. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Usana Health Sciences. This is 180% above median its historical median of 0.05. Over the past decade, Usana Health Sciences' Debt-to-EBITDA has ranged from 0.04 to 0.29. According to the industry distribution chart, Usana Health Sciences ranks #181 out of 1550 companies in the Consumer Packaged Goods industry, placing it in the top 11.7%.
Is Usana Health Sciences' Debt-to-EBITDA too high?
Usana Health Sciences' current Debt-to-EBITDA of 0.14 is 180% above median its 10-year median of 0.05. Over the past 10 years, this metric has ranged from a low of 0.04 to a high of 0.29. The Consumer Packaged Goods industry median Debt-to-EBITDA is 2.08. Usana Health Sciences' value of 0.14 is 93.3% below this industry median. Based on the distribution chart, Usana Health Sciences ranks #181 out of 1550 companies in the Consumer Packaged Goods industry, which is in the top quartile — a strong position relative to peers. Overall, Usana Health Sciences has a GF Score™ of 68/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Usana Health Sciences' Debt-to-EBITDA compare to ENHA and NATR?
According to the Consumer Packaged Goods industry distribution chart, Usana Health Sciences ranks #181 out of 1550 companies for Debt-to-EBITDA. This places Usana Health Sciences in the top 12% of its industry — outperforming the majority of peers. The industry median Debt-to-EBITDA is 2.08. Usana Health Sciences' value of 0.14 is 93.3% below this benchmark. Historically, Usana Health Sciences' own Debt-to-EBITDA has ranged from 0.04 to 0.29 over the past decade. While the company's 10-year median is 0.05 vs. the industry median of 2.08, Usana Health Sciences has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-EBITDA for a Consumer Packaged Goods company?
The median Debt-to-EBITDA among Consumer Packaged Goods companies is 2.08, based on 1,550 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Usana Health Sciences's current Debt-to-EBITDA of 0.14 is 93.3% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-EBITDA mean?
A high Debt-to-EBITDA can signal that a stock is expensive relative to its fundamentals. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Usana Health Sciences. For the Consumer Packaged Goods industry, the median Debt-to-EBITDA is 2.08 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Usana Health Sciences's current Debt-to-EBITDA is 0.14, which is 180% above median its own 10-year median of 0.05. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Usana Health Sciences stock overvalued right now?
Based on GuruFocus' analysis, Usana Health Sciences (USNA) is currently considered Possible Value Trap. The stock's GF Value™ is $41.46, compared to a current price of $22.11 — trading 46.7% below its estimated fair value. The current Debt-to-EBITDA is 0.14, which is 180% above median its 10-year median of 0.05 and 93.3% below the Consumer Packaged Goods industry median of 2.08. Usana Health Sciences' overall GF Score™ is 68/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-EBITDA calculated?
Debt-to-EBITDA is calculated from a company's financial statements. For Usana Health Sciences (USNA), the current Debt-to-EBITDA is 0.14 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Usana Health Sciences (USNA) Overvalued in 2026?
Based on GuruFocus' analysis, Usana Health Sciences stock appears to be undervalued.
The current stock price of $22.11 is trading 46.7% below its estimated GF Value™ of $41.46.
GuruFocus considers Usana Health Sciences to be Possible Value Trap.
Key valuation signals for USNA:
Debt-to-EBITDA: 0.14 (180% above median its 10-year median of 0.05)
GF Value™: $41.46 vs. price of $22.11 (46.7% below fair value)
Industry Position: 93.3% below the Consumer Packaged Goods median (#181 of 1550)
No single metric tells the full story. See the USNA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Usana Health Sciences Inc develops and manufactures high-quality nutritional supplements, functional foods, and personal care products that are sold throughout the world. The company has developed and manufactured high-quality, science-based nutritional, personal care, and skincare products with a primary focus on promoting long-term health and wellness. The Company's reporting units for goodwill purposes are tied to its reportable segments: Core nutritional and Hiya direct-to-consumer. The core nutritional segment consists of three individual reporting units that are determined based on the operational nature of the business: Buy-Sell, China, and India. Geographically, it is in Asia Pacific, the Americas, and Europe. With the majority of revenue from Asia Pacific(Greater China).
68GF Score
Get the complete analysis for USNA
Debt-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
USNA has been successfully added to your 
